Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan cilexetil dose-ranging study in hypertensive children aged 1 to under 6 years
2004-004264-75Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of candesartan in hypertension (HTN) (4 arms), sponsored by AstraZeneca. Primary endpoints: Primary efficacy endpoint and Dose-response by body weight panel. Started Jun 2005; status: completed.
02
Drugs
candesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2004-004264-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004264-75.